Study of NMS-03305293, a Non-Trapping PARP1-Specific PARP Inhibitor in Relapsed Small Cell Lung Cancer

Cancer: Lung
Study Phase: phase 1
Status: recruiting
Sponsor: Nerviano Medical Sciences
ClinicalTrials.gov Identifier: NCT06931626
Disease Focus: Small Cell Lung Cancer
Principal Investigator: Jun Zhang MD PhD
Clinical Research Coordinator: Vishnu JaiShree Mohandas MBBS MPH

Study Overview

This is an open-label study of NMS-03305293 with Temozolomide (TMZ) in patients with Small Cell Lung Cancer (SCLC). The aim of this study is to determine the safety and tolerability, as well as to evaluate the anti-tumor efficacy and pharmacokinetics of NMS-03305293 in combination with TMZ.

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

clinicaltrials.gov NCT:NCT06931626

Interested in Participating in this Trial?

If you are interested in participating in this study, call the OSF Hope line at (844) 673- 4467 or email: sfmc.clinicaltrials@osfhealthcare.org